Cargando…

Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma

Resistance to targeted therapy is a well known obstacle in cancer therapy. The cross-talk between several growth factor receptors generates redundancy in their intracellular pathways that usually mediates resistance to receptor targeted therapy. Simultaneous inactivation of two or more growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	PURCARU, S.O., TACHE, D.E., SERBAN, F., FOLCUTI, R.M., GEORGESCU, A.M., STOVICEK, P.O., DANCIULESCU, M.M., TATARANU, L.G., DRICU, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medical University Publishing House Craiova 2015
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243508/ https://www.ncbi.nlm.nih.gov/pubmed/30538838 http://dx.doi.org/10.12865/CHSJ.41.04.06

Ejemplares similares

The Effect of Human Mesenchymal Stem Cells-Conditioned Media on Glioblastoma Cells Viability In Vitro
por: FOLCUTI, R.M., et al.
Publicado: (2015)

Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials
por: Artene, Stefan-Alexandru, et al.
Publicado: (2018)

The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma
por: Alexandru, Oana, et al.
Publicado: (2018)

Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker
por: Serban, Florentina, et al.
Publicado: (2015)

Biobanking in a Constantly Developing Medical World
por: Artene, Stefan-Alexandru, et al.
Publicado: (2013)

Plasma Levels of Glucose and Insulin in Patients with Brain Tumors
por: ALEXANDRU, OANA, et al.
Publicado: (2014)

Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines
por: Alexandru, Oana, et al.
Publicado: (2019)

Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)
por: Sevastre, Ani-Simona, et al.
Publicado: (2021)

New perspectives in glioblastoma antiangiogenic therapy
por: Popescu, Alisa Madalina, et al.
Publicado: (2015)

Correlation between Tgf-Β1 and Fsp-1 Expression in Chronic Viral Hepatitis - an Immunohistochemical Study
por: TACHE, D.E., et al.
Publicado: (2015)

The Potential of Helianthin Loaded Into Magnetic Nanoparticles to Induce Cytotoxicity in Glioblastoma Cells
por: COSTACHI, ALEXANDRA, et al.
Publicado: (2021)

Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine
por: Kratzsch, Tobias, et al.
Publicado: (2020)

Cancer Stem Cells: Biological Functions and Therapeutically Targeting
por: Ciurea, Marius Eugen, et al.
Publicado: (2014)

β-arrestin 1 Overexpression Increases Temozolomide Resistance in Human Malignant Glioma Cells
por: ARTENE, S.A., et al.
Publicado: (2017)

The effect of Azo-dyes on glioblastoma cells in vitro
por: Sevastre, Ani-Simona, et al.
Publicado: (2023)

Relationship Status Update on Astrocytic VEGFR-3 and mTOR Signaling: It’s Complicated
por: Brewster, Amy L.
Publicado: (2021)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

Clinical and Pathological Analysis of Two Cases of Cutaneous Malignant Melanoma
por: BLENDEA, A., et al.
Publicado: (2015)

Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway
por: Ji, Lijun, et al.
Publicado: (2018)

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
por: Chu, Jie Sheng, et al.
Publicado: (2013)

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome
por: Estevez-Garcia, Purificacion, et al.
Publicado: (2012)

Glioblastoma Stem Cells—Useful Tools in the Battle against Cancer
por: Rodriguez, Silvia Mara Baez, et al.
Publicado: (2022)

The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer
por: Purcaru, Oana-Stefana, et al.
Publicado: (2021)

Arsenic reverses glioblastoma resistance to mTOR-targeted therapies
por: Iwanami, Akio, et al.
Publicado: (2013)

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
por: Mecca, Carmen, et al.
Publicado: (2018)

An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model
por: Oshiro, Hiromichi, et al.
Publicado: (2021)

Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma
por: Setyo, Laura C., et al.
Publicado: (2023)

Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment
por: Dumas, Anaelle A, et al.
Publicado: (2020)

Combined Effects of Doxorubicin and Temozolomide in Cultured Glioblastoma Cells
por: BALOI, CARINA, et al.
Publicado: (2022)

Intracellular Pathways and Mechanisms of Colored Secondary Metabolites in Cancer Therapy
por: Sevastre, Ani-Simona, et al.
Publicado: (2022)

Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology–morphological and therapeutic implications
por: Georgescu, Maria-Magdalena, et al.
Publicado: (2019)

mTOR inhibition impairs extinction memory reconsolidation
por: Radiske, Andressa, et al.
Publicado: (2021)

An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma
por: Rodriguez, Silvia Mara Baez, et al.
Publicado: (2023)

mTOR signaling in glioblastoma: lessons learned from bench to bedside
por: Akhavan, David, et al.
Publicado: (2010)

mTOR Modulates Intercellular Signals for Enlargement and Infiltration in Glioblastoma Multiforme
por: Ryskalin, Larisa, et al.
Publicado: (2020)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
por: Papavassiliou, Kostas A., et al.
Publicado: (2021)

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor
por: Michael, M, et al.
Publicado: (2010)

Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
por: Berardi, Rossana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4ljc0rbr0jnb85p3k6difmgide